A PHASE1/1B FIRST-IN-HUMAN DOSE ESCALATION AND EXPANSION STUDY FOR THE EVALUATION OF SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF SAR439459 ADMINISTERED INTRAVENOUSLY AS MONOTHERAPY AND IN COMBINATION WITH CEMIPLIMAB IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS.
2018-001113-32TUMORES SÓLIDOS AVANZADOSFundación Jiménez DíazInvestigador: DOGER DE SPEVILLE BERNARD
